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Abstract .  The purpose of the present study was to correlate the wavelength of the irradiation 
source with the phototoxic activity of tetra(m-hydroxyphenyl)chlorin (mTHPC) in healthy and 
neoplastic mucosae. The hamster tumour model for early squamous cell carcinoma was used in 
these experiments. In vitro and in vivo studies have shown that mTHPC absorbs significantly at 
652 nm (1, 2). This wavelength is used currently in clinical mTHPC photodynamic therapy (PDT) 
trials. In order to study the wavelength dependence of the phototoxic effect on normal and tumour 
tissues, irradiation tests were performed 4 days after injection of 0.5mg kg -1 mTHPC. An 
argon-ion pumped ye laser was used as the light source. The light dose of 12 J cm-  2 was delivered 
at a light dose rate of 150 mW cm - 2. The wavelength was varied between 642.5 and 665 nm at 2.5-nm 
increments. The PDT damage was evaluated in serial Haematoxylin and Eosin stained sections 
using a tissue-damage scale. Light between 647.5 and 652.5 nm induced the highest damage to both 
the healthy and tumour mucosae. At wavelengths equal to or below 645 nm, and equal to or above 
655 nm, tissue damage decreased. Wavelengths below 642 nm and above 660 nm did not induce any 
visible tissue damage. These results suggest hat the in vivo optimal wavelength range for PDT 
with mTHPC is between 647 and 652 nm. This information is essential for selecting an appropriate 
light source. 
INTRODUCTION 
Photodynamic therapy (PDT) is emerging as a 
minimally invasive alternative for the treat- 
ment of early squamous cell carcinomas 
(SCCs) in hollow organs (3~). In head and 
neck cancers, the advantage of PDT compared 
to conventional modalities, such as surgery, 
radiation or chemotherapy, lies in the preven- 
tion of excessive tissue loss and of significant 
functional disorders (7). 
Successful PDT involves the optimization of 
a large number of parameters. Among them are 
the type of photosensitizer (PS) including the 
mode and vehicle used for its administration, 
the drug dose, the wavelength of the light, 
the light dose, the light dose rate and the 
drug-light interval. In addition to these par- 
ameters, the wavelength of the light used in 
PDT is obviously crucial for optimizing the 
therapeutic effect. As it is difficult to evaluate 
all of these variables in a clinical context, the 
use of an animal model may provide preclinical 
data relevant o clinical trials of PDT. For this 
reason, 'early' SCCs, chemically induced using 
7,12-dimethylbenz(a)anthracene (DMBA) in 
the cheek pouch of the Syrian hamster (8), have 
been chosen for this study. In both histology 
and immunohistochemistry, this tumour model 
mimics human carcinogenesis in the upper 
aero-digestive tract and oesophagus (9-11). 
Wavelength dependence has been studied 
in vivo and in vitro with different second- 
generation PSs such as phthalocyanines 
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Fig. 1. Light distributor used for irradiation of the hamster cheek pouch mucosa. 
(12, 13), BPD-MA (14) and 5-ALA (15). With 
many PSs, wavelength shifts are observed 
between the absorption maxima measured in 
solvents and the most effective PDT wave- 
length in vivo (12, 13). Such shifts can be due 
to different factors such as the localization of 
the PS in different issues and tissue compart- 
ments as well as tissue absorption properties, 
the production of singlet oxygen, or the 
physico-chemical environment (16). 
To measure the PDT 'action spectrum' 
around 652 nm, irradiation tests between 642.5 
and 665 nm were performed. Results were com- 
pared with the fluorescence xcitation spec- 
trum of mTHPC measured in vivo, and its 
absorption spectrum measured in vitro (1, 2). 
To the best of the authors' knowledge, this 
information is not available for mTHPC. 
Photodynamic therapy 
Tetra(m-hydroxyphenyl)chlorin (mTHPC) was 
supplied in powder form by Scotia Pharmaceu- 
ticals Ltd (Guildford, UK). Prior to utilization, 
it was dissolved in a solution of 30% v/v 
polyethylene glycol 400, 20% v/v ethanol and 
50% v/v H20. Photodynamic therapy on 
tumour-bearing and contralateral healthy 
cheek pouch mucosae was performed 4 days 
after an intracardiac injection of 0.5 mg kg - 1 
body weight mTHPC (18). Irradiation con- 
ditions were adapted to those applied in clini- 
cal trials (19). The light dose of 12 J cm-  2 was 
delivered at a rate of 150 mW cm - 2. This light 
intensity is not sufficient o induce a thermal 
effect in tissues (20). Photodynamic therapy 
was carried out with wavelengths between 
642.5 and 665 nm at 2.5-nm increments. 
MATERIALS AND METHODS 
Animal model 
Carcinogenesis in the hamster cheek pouch 
was chemically induced (BRL, Fuellinsdorf, 
Switzerland) according to methods that have 
been described previously (17). Briefly, the 
early SCC (carcinoma in situ and micro- 
invasive carcinoma) was produced by topical 
application of 0.5% oily DMBA (Sigma 
Chemicals Co. St Louis, USA) solution in the 
left cheek pouch mucosa thrice weekly over 
10 weeks. The contralateral cheek pouch, 
which was not painted with DMBA, served as 
control. The animals were housed at room 
temperature with a 12-h light/dark cycle. Food 
and drinking water were given ad libitum. All 
experiments were performed under intraper- 
itoneal anaesthesia (ketalar 150mg kg -1 
and xylesine 15 mg kg-1) and in accordance 
with protocols approved by the experimental 
animal ethics committee. 
Light source and light delivery 
An argon-ion pumped ye laser system [Spectra- 
Physics Model 2045 (20 W continuous wave in 
the visible) and Spectra-Physics Model 375 B 
dye laser], operated with 4-dicyanomethylene- 
2-methyl- 6- (p- dimethylamino styryl)- 4H-pyran 
(DCM) dye (LC 6500 from Lambda Physics) was 
used as the light source. The DCM dye allows 
the laser to be tuned between 600 and 695 nm. 
The wavelength is tuned with a birefringent 
filter (Spectra-Physics, Model 573-94) located 
in the dye laser cavity, and the wavelength is 
verified with a monochromator [Jobin-Yvon, 
Model H 10, Precision: 0.2 nm full width half 
maximum (FWHM)]. The light was applied 
using a 1 cm diameter cylindrical distributor 
equipped with a lateral circular window 
(Fig. 1). The light delivered by an optical 
quartz fibre to the light diffuser is expanded 
through a small air space, and passes into a 
cylindrical rod that contains a transparent 
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silicone polymer loaded with A120 3 particles in 
order to scatter the light. The aluminium end 
mirror and the concentration of particles 
along the main axis of this cylinder are chosen 
to give a homogenous light distribution at the 
surface of the outer cylinder. Careful position- 
ing of the light diffuser in the hamster cheek 
pouch in direct contact with the buccal 
mucosa offers a high reproducibility in the 
light dosimetry. 
Analysis of PDT-induced tissue damage 
Table 1. Tissue damage scale 
Grade of 
tissue damage 
Histology 
No tissue destruction 
Destruction of the epithelium 
Destruction of the epithelium 
and the lamina propria 
Destruction of the epithelium, 
the lamina propria and the 
striated muscle 
Destruction of all layers resulting 
in transmural necrosis 
The animals were killed, using an overdose of 
the same anaesthetics as mentioned above, 
96h after irradiation, which corresponds to 
the time of maximal mucosal damage. The 
procedure used for taking biopsies has been 
described previously (21). The entire tumoral 
and healthy cheek pouches were resected, and 
lesions were divided into two equal specimens. 
One was fixed in 5% buffered formalin (pH 7.0), 
paraffin-embedded, sectioned in 5-/~m thick 
slices and stained with Haematoxylin and 
Eosin (H&E) for standard histological exami- 
nation. For each animal, the whole necrotic 
area was examined in serial sections stained 
with H&E to evaluate the depth of the mucosal 
destruction. The other part of the excised 
lesion was frozen immediately in liquid nitro- 
gen by contact with an isopentane slush, and 
cut at cryogenic temperatures in 5-/~m thick 
slices. These were used in some cases for 
additional histochemical myosin-ATP-ase and 
NADH-diaphorase staining techniques, which 
are especially useful for assessing the degree of 
damage to striated muscles (22, 23). Following 
the enzymatic reaction, counterstaining 
with Haemalun allowed the delineation 
between necrotic and healthy layers to be 
demonstrated. 
In order to evaluate the histological depth 
of PDT damage on different mucosal ayers, 
such as epithelium, lamina propria or striated 
muscle, a four-graded tissue-damage scale was 
used. On this scale, Grade 1 corresponds to the 
destruction of the epithelium. In Grade 2, the 
necrosis extends to the lamina propria. Grade 
3 corresponds to a necrosis that reaches the 
striated muscle, and in Grade 4, all mucosal 
layers are destroyed. Tissue damage up to 
Grade 2 was estimated as an insufficient effect. 
Grades 2 and 3 were judged as an 'optimal' 
PDT response, and Grade 4 necrosis was 
considered to be an overdose response. The 
Grades 0 and 1 are estimated asinsufficient, 2 and 3 as 
optimal and 4 as overdose r sponses. 
grades of necrosis and evaluation of the tissue 
damage are summarized in Table 1. This non- 
linear, morphological scale has been chosen 
because massive (although not always 
observed) interstitial oedema of the mucosal 
wall hinders reproducible micrometric 
measurements of the tissue damage. This 
means that when a marked oedema is present, 
the absolute measurement of the depth of 
necrosis could be increased artificially as 
compared to the same necrosis in a 
non-oedematous cheek pouch. 
Statistical analysis 
The results of irradiation performed on the 
healthy and tumour mucosae were evaluated 
as depths of tissue damage graded from 0 to 4 
using the scale described above. The statisti- 
cal significance of the differences in tissue 
responses achieved at various wavelengths 
was determined using a non-parametric Mann- 
Whitney U-test (a_< 0.05). 
RESULTS 
Macroscopically, the first changes in the ir- 
radiated mucosae were observed 24h after 
PDT as a diffuse oedema of the whole cheek 
pouch. The first visible tissue reaction match- 
ing the irradiation window appeared 48h 
later, and achieved a maximum at 96 h after 
PDT. Figure 2 illustrates the results of the 
irradiation in terms of tissue damage to 
the healthy and neoplastic mucosae at 
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Fig. 2. Damage induced by photodynamic therapy (PDT) 
on healthy and neoplastic hamster cheek pouch mucosae 
4 days after injection of 0.5 mg kg -~ mTHPC. The fluence of 
12 J cm -2 was delivered at a fluence rate of 150 mW cm -2. 
The wavelength was varied from 642.5 to 665 nm in 2.5-nm 
increments. Light delivered between 647.5 and 652.5 nm 
induced maximal damage to both tumour-bearing (O) and 
healthy (o) mucosae. At these wavelengths, significantly 
higher PDT damage was noted for early squamous cell 
carcinoma as compared to the healthy mucosa (a<0.05). At 
645, 655 and 657 nm, less pronounced tissue damage was 
observed for both mucosae. Light applied at wavelengths 
below 642.5 and over 660 nm did not induce any visible 
tissue damage. Data points represent mean tissue damage 
for five animals, as determined by the rating scale 
described in the text. Error bars are • standard deviation. 
The significance of the differences in tissue responses 
achieved at various wavelengths was determined using a 
non-parametric Mann-Whitney U-test (eL<0.05). 
wavelengths ranging from 642.5 to 665nm. 
Light delivered between 647.5 and 652.5 nm 
induced maximal damage to both the healthy 
and tumour-bearing mucosae. At these wave- 
lengths, significantly higher damage from PDT 
was noted for early SCC as compared to the 
healthy mucosa (a_< 0.05). With the same light 
dose delivered at 645, 655 and 657 nm, less 
pronounced tissue damage was observed for 
both mucosae (a_<0.05). Light at wavelengths 
below 642.5 and over 660 nm did not induce any 
visible tissue damage. 
DISCUSSION 
This in vivo study has shown that in the red 
part of the spectrum, wavelengths between 647 
and 652nm induce the greatest amount of 
tissue damage in both the healthy and tumour- 
bearing mucosae. The range of wavelengths 
(647-652 rim) over which PDT of early SCC is 
most effective in this particular tumour model 
suggests that for early cancers in hollow 
organs, fairly broad-band light sources can be 
used while retaining a maximum phototoxic 
effect. 
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Fig. 3. The in vitro absorption spectrum of 5 ~M mTHPC in 
phosphate-buffered saline (PBS) solution supplemented 
with 10% bovine serum (o) as well as the in vivo 
fluorescence excitation spectrum (<>) and the photodynamic 
therapy tissue damage 'action spectrum' (D) are compared. 
The fluorescence excitation peaks are at nearly the same 
wavelengths as the absorption peaks (absorption in vitro 
652+1 nm and fluorescence excitation in vivo 651 • nm). 
Fluorescence excitation and absorption curves have 
patterns in the red region (647-652 nm) that are similar to 
those of the tissue-damage curve. 
The mTHPC-PDT tissue damage curve can be 
compared to either the in vitro absorption spec- 
trum or the in vivo excitation signal as shown 
in Fig. 3. The in vitro absorption curve of 5 ~M 
mTHPC in phosphate-buffered saline (PBS) sup- 
plemented with 10% bovine serum shows its 
absorption maximum in the red to be 652 nm 
(1, 2, 24). The in vivo fluorescence xcitation 
spectrum of mTHPC measured with a fibre- 
based optical multichannel analyser (25) on 
the healthy and tumour-bearing cheek pouch 
mucosae has a fluorescence excitation peak at 
nearly the same wavelength (M. Forrer, 
unpubl, data). The slight difference between 
these spectra can be attributed to two factors: 
first, the difference in precision of the two 
methods used; and second, the influence of the 
optical tissue absorption and scattering on the 
fluorescence excitation spectra (26). The fluor- 
escence absorption and excitation spectra are 
similar in form to the tissue-damage curve. The 
region of pronounced tissue damage is situated 
between 647.5 and 652.5 nm. These wavelengths 
correspond to equal fluorescence xcitation 
and absorption intensities on either side of the 
fluorescence xcitation and absorption max- 
ima. In contrast o observations reported for 
some of the other compounds used in PDT (1), 
there seems to be no wavelength shift between 
the absorption, excitation and tissue-damage 
response curves in the red part of the spectrum. 
In the present experiments, the highest PDT 
efficacy was achieved at wavelengths of 
mTHPC in Early Squamous Cell Carcinoma 
650 • 2.5 nm using an argon-ion pumped dye 
laser with a 0.2 nm FWHM. Recent develop- 
ments in diode laser technology offer high- 
power devices with several nanometre 
bandwidths (27). The results obtained here 
suggest hat such diode lasers can be used as 
appropriate light sources without a significant 
loss of PDT efficacy. 
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